|
|
|
|
|
|
| About Max Cummings (Tibotec Pharmaceuticals) |
|
Max Cummings is a Principal Scientist in the Computational Virology and Chembioinformatics group at Tibotec where he is engaged in structure-based drug discovery and design. In addition to supporting various medicinal chemistry projects, his ongoing research interests include protein-protein interactions and small molecule docking.
Max earned his B.Sc. in Chemistry from the University of Winnipeg (1985), M.Sc. in Chemistry from the University of Manitoba (1988) and Ph.D. in Biochemistry from the University of Alberta (1996). His undergraduate and M.Sc. research was in the area of mechanistic enzymology related to acetylcholinesterase. He worked in medicinal chemistry and enzymology at SynPhar Laboratories, Inc., Edmonton from 1988-1996, and in the Department of Biochemistry at the University of Alberta from 1992-1997. His Ph.D. research focused on biochemical applications of modeling and docking. In 1997 Dr. Cummings joined the computational chemistry group at SmithKline Beecham, King of Prussia, USA and in 2000 moved to 3-Dimensional Pharmaceuticals, Exton, USA, which later become part of Johnson & Johnson PRD. In 2007 he moved to Tibotec BVBA, a Johnson & Johnson company, in Mechelen, Belgium.
|
| |
|
|
|
|
|
|
|
|
